The ROE as of September 2024 (TTM) for Alnylam Pharmaceuticals, Inc. (ALNY) is 47.92%

According to Alnylam Pharmaceuticals, Inc.’s latest financial reports and current stock price. The company's current ROE is 47.92%. This represents a change of -65.41% compared to the average of 138.54% of the last 4 quarters.

Alnylam Pharmaceuticals, Inc. (ALNY) Historical ROE (quarterly & annually)

How has ALNY ROE performed in the past?

The mean historical ROE of Alnylam Pharmaceuticals, Inc. over the last ten years is 43.11%. The current 47.92% ROE has changed 11.15% with respect to the historical average. Over the past ten years (40 quarters), ALNY's ROE was at its highest in in the September 2022 quarter at 600.14%. The ROE was at its lowest in in the June 2022 quarter at -157.58%.

Alnylam Pharmaceuticals, Inc. (ALNY) ROE by Quarter and Year

Discovering the peaks and valleys of Alnylam Pharmaceuticals, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Alnylam Pharmaceuticals, Inc. (ALNY) Average ROE

How has ALNY ROE performed in the past?

The current ROE of Alnylam Pharmaceuticals, Inc. (ALNY) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

Alnylam Pharmaceuticals, Inc. (ALNY) ROE vs. Peers

How is ALNY’s ROE compared to its peers?

Alnylam Pharmaceuticals, Inc.’s ROE is greater than ProQR Therapeutics N.V. (-55.21%), greater than Wave Life Sciences Ltd. (-657.91%), greater than Blueprint Medicines Corporation (-85.25%), greater than Apellis Pharmaceuticals, Inc. (-139.02%), less than Incyte Corporation (2.10%), less than United Therapeutics Corporation (18.82%), greater than Ultragenyx Pharmaceutical Inc. (-266.02%), less than BioMarin Pharmaceutical Inc. (5.08%), greater than Seagen Inc. (-28.06%), less than Exelixis, Inc. (15.80%), less than Halozyme Therapeutics, Inc. (168.60%), less than Krystal Biotech, Inc. (13.36%), greater than Madrigal Pharmaceuticals, Inc. (-95.61%), less than Reata Pharmaceuticals, Inc. (19.32%), greater than IVERIC bio, Inc. (-38.66%), greater than Amylyx Pharmaceuticals, Inc. (-46.15%), greater than Karuna Therapeutics, Inc. (-30.79%), greater than Day One Biopharmaceuticals, Inc. (-122.70%),

Build a custom stock screener for Alnylam Pharmaceuticals, Inc. (ALNY) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Alnylam Pharmaceuticals, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Alnylam Pharmaceuticals, Inc. (ALNY) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Alnylam Pharmaceuticals, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.